Shortage Watch Free FDA drug-shortage watch

← all medications

Insulin Glargine Injection

Category: Endocrinology/Metabolism

Not specified 1

FDA status: To Be Discontinued · Last FDA update: Oct 24, 2025 · First posted: Oct 24, 2025 · 1 manufacturers, 1 listed presentations

As of Oct 24, 2025, the FDA lists Insulin Glargine Injection as being discontinued. Of 1 manufacturer presentations, 1 Not specified.

Ask your pharmacist: which of the 1 manufacturers below can they order right now, and whether a different strength or form of Insulin Glargine Injection is available. For alternatives, talk to your prescriber — see what to do if your medication is in shortage.
Presentation & package NDCManufacturerAvailabilityFDA note
Basaglar, Injection, U-100 Tempo Pen (NDC 0002-8214-05)
NDC 0002-8214-05		 Eli Lilly and Co. Not specified A business decision was made to discontinue manufacture of the drug.

Related medications in shortage

Other Endocrinology/Metabolism medications currently on the FDA shortage list — useful context if you and your prescriber are weighing alternatives. Always confirm with your pharmacist.

Change log

No changes recorded yet.
Tracking began Oct 1, 2026. We check the FDA every 6 hours; any real change - a manufacturer moving from Limited to Available, a new recovery date, a new listing - shows up here with its date.

Cite this: “FDA drug-shortage status for Insulin Glargine Injection (FDA data as of Oct 24, 2025). Shortage Watch, openFDA.”

Get an email when this record changes

One email, only when the FDA changes something for Insulin Glargine Injection. You confirm by clicking a link first (double opt-in). No newsletter, no other mail.

Check your inbox - click the confirmation link to activate alerts for Insulin Glargine Injection.

Feeds instead of email: RSS or JSON. Unsubscribe anytime; see Privacy.

Embed a live status badge: /badge/insulin-glargine-injection.svg

FDA data last synced Oct 1, 2026 (FDA record dated Sep 30, 2026).